134 related articles for article (PubMed ID: 21974973)
1. Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study.
Margolis JM; Fowler R; Johnson BH; Kassed CA; Kahler K
BMC Neurol; 2011 Oct; 11():122. PubMed ID: 21974973
[TBL] [Abstract][Full Text] [Related]
2. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database.
Prescott JD; Factor S; Pill M; Levi GW
J Manag Care Pharm; 2007; 13(1):44-52. PubMed ID: 17269836
[TBL] [Abstract][Full Text] [Related]
3. Utilization Patterns of Oral Disease-Modifying Drugs in Commercially Insured Patients with Multiple Sclerosis.
Desai RJ; Mahesri M; Gagne JJ; Hurley E; Tong A; Chitnis T; Minden S; Spettell CM; Matlin OS; Shrank WH; Choudhry NK
J Manag Care Spec Pharm; 2019 Jan; 25(1):113-121. PubMed ID: 30589630
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with early initiation of disease-modifying drug treatment in newly-diagnosed patients with multiple sclerosis.
Edwards NC; Munsell M; Menzin J; Phillips AL
Curr Med Res Opin; 2018 Aug; 34(8):1389-1395. PubMed ID: 29493313
[TBL] [Abstract][Full Text] [Related]
5. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Bonafede MM; Johnson BH; Wenten M; Watson C
Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
[TBL] [Abstract][Full Text] [Related]
6. Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study).
Jongen PJ; Hengstman G; Hupperts R; Schrijver H; Gilhuis J; Vliegen JH; Hoogervorst E; van Huizen M; van Munster E; Samijn J; de Schryver E; Siepman T; Tonk M; Zandbergen E; ten Holter J; van der Kruijk R; Borm G
BMC Neurol; 2011 Mar; 11():40. PubMed ID: 21450086
[TBL] [Abstract][Full Text] [Related]
7. Use of an early disease-modifying drug adherence measure to predict future adherence in patients with multiple sclerosis.
Kozma CM; Phillips AL; Meletiche DM
J Manag Care Spec Pharm; 2014 Aug; 20(8):800-7. PubMed ID: 25062073
[TBL] [Abstract][Full Text] [Related]
8. The association of timing of disease-modifying drug initiation and relapse in patients with multiple sclerosis using electronic health records.
Corvino FA; Oliveri D; Phillips AL
Curr Med Res Opin; 2017 Jun; 33(6):1127-1132. PubMed ID: 28318337
[TBL] [Abstract][Full Text] [Related]
9. Using observational analysis of multiple sclerosis relapse to design outcomes-based contracts for disease-modifying drugs: a feasibility assessment.
Lage MJ; Carroll CA; Fairman KA
J Med Econ; 2013 Sep; 16(9):1146-53. PubMed ID: 23844620
[TBL] [Abstract][Full Text] [Related]
10. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs.
Reynolds MW; Stephen R; Seaman C; Rajagopalan K
J Med Econ; 2010 Mar; 13(1):90-8. PubMed ID: 20078189
[TBL] [Abstract][Full Text] [Related]
11. Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs.
Birnbaum HG; Ivanova JI; Samuels S; Davis M; Cremieux PY; Phillips AL; Meletiche D
Curr Med Res Opin; 2009 Apr; 25(4):869-77. PubMed ID: 19232041
[TBL] [Abstract][Full Text] [Related]
12. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US.
Ivanova JI; Bergman RE; Birnbaum HG; Phillips AL; Stewart M; Meletiche DM
J Med Econ; 2012; 15(3):601-9. PubMed ID: 22376190
[TBL] [Abstract][Full Text] [Related]
13. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
[TBL] [Abstract][Full Text] [Related]
14. The impact of persistence with therapy on inpatient admissions and emergency room visits in the US among patients with multiple sclerosis.
Thomas NP; Curkendall S; Farr AM; Yu E; Hurley D
J Med Econ; 2016; 19(5):497-505. PubMed ID: 26706292
[TBL] [Abstract][Full Text] [Related]
15. Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US.
Krysko KM; Graves J; Rensel M; Weinstock-Guttman B; Aaen G; Benson L; Chitnis T; Gorman M; Goyal M; Krupp L; Lotze T; Mar S; Rodriguez M; Rose J; Waltz M; Charles Casper T; Waubant E;
Neurology; 2018 Nov; 91(19):e1778-e1787. PubMed ID: 30333163
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of practice patterns in the treatment of atrial fibrillation among the commercially insured.
Liu J; Sylwestrzak G; Barron J; Rosenberg A; White J; Whitney J; Redberg R; Malenka D
Curr Med Res Opin; 2014 Sep; 30(9):1707-13. PubMed ID: 24809834
[TBL] [Abstract][Full Text] [Related]
17. Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
Bergvall N; Lahoz R; Reynolds T; Korn JR
Curr Med Res Opin; 2014 Aug; 30(8):1461-71. PubMed ID: 24754349
[TBL] [Abstract][Full Text] [Related]
18. Updated cost-of-care estimates for commercially insured patients with multiple sclerosis: retrospective observational analysis of medical and pharmacy claims data.
Carroll CA; Fairman KA; Lage MJ
BMC Health Serv Res; 2014 Jul; 14():286. PubMed ID: 24986083
[TBL] [Abstract][Full Text] [Related]
19. Adherence to multiple sclerosis disease-modifying therapies in Ontario is low.
Wong J; Gomes T; Mamdani M; Manno M; O'Connor PW
Can J Neurol Sci; 2011 May; 38(3):429-33. PubMed ID: 21515501
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
